Cancer Management and Research
Volume 11, 2019 - Issue
Open access
160
Views
30
CrossRef citations to date
0
Altmetric
Review
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Jan Philipp Bewersdorf1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA
https://orcid.org/0000-0003-3352-0902
Sara Mohamed Jaszczur2 Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA
, Salma Afifi2 Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA
https://orcid.org/0000-0002-1556-1025
Jennifer C Zhao2 Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA
https://orcid.org/0000-0002-7342-5785
Amer M Zeidan1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA;3 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USACorrespondence[email protected]
Pages 10777-10790
|
Published online: 24 Dec 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.